They have also demonstrated that in the early stage of acute myocardial ischemia, SGLT2 inhibitors reduce the myocardial infarct size through activation of the signal transducer and activator of transcription 3 and downregulation of inflammatory responses in the infarcted myocardium3. Here, SLC5A2 is linked to myocardial infarction.